• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    5/23/25 5:00:13 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    upxi_8k.htm
    0001775194false00017751942025-05-222025-05-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    _________________

     

    FORM 8-K

    _________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  May 22, 2025

     

    _______________________________

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

    _______________________________

     

    Nevada

     

    001-40535

     

    83-3378978

    (State or Other Jurisdiction

     of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3030 Rocky Point Drive, Suite 420

    Tampa, Florida 33607

    (Address of Principal Executive Offices) (Zip Code)

     

    (701) 353-5425

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001

     

    UPXI

     

    NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On May 22, 2025 (the “Effective Date”), Upexi, Inc., a Nevada corporation (the “Company”), appointed Brian Rudick as Chief Strategy Officer (CSO) of the Company.

     

    Brian Rudick CFA, 43, Chief Strategy Officer. Mr Rudick joined Upexi, Inc. in May 2025 and brings deep expertise and connectivity in both traditional finance and crypto alike. Most recently, Mr. Rudick served as Head of Research for GSR, the largest digital asset market maker, where he demonstrated thought leadership externally and led internal business initiatives, including GSR’s lead investment into Upexi’s $100 million private placement. Prior to GSR, Mr. Rudick spent over a decade on Wall Street, primarily managing a long-short portfolio of bank stocks as a key member of financials-focused teams at Citadel, Balyasny, and Millennium. Mr. Rudick started his career at the Federal Reserve, where he conducted research as part of the monetary policy process. He holds a BSc from Duke University, an MBA from The University of Chicago, and is a CFA Charter holder.

     

    Pursuant to the employment terms, Brian Rudick will be paid an annual salary of $300,000 and additional cash and equity performance bonuses per year. In addition, Brian Rudick will be paid $950,000 in structured cash payments through December 31, 2025 and will be granted 400,000 shares of restricted stock that will vest during his first year of employment. The initial term of employment is one year, that will automatically renew for one year period if not terminated by Brian Rudick or the Company.

     

    Section 9 – Financial Statements and Exhibits

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit No.

    Exhibit Description

    99.1

    Press Release of Upexi, Inc., dated May 22, 2025

    99.2

     

    Brian Rudick Employment Agreement, dated May 22, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

     

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Date: May 23, 2025

    By: 

    /s/ Andrew Norstrud 

     

     

     

    Andrew Norstrud

     

     

     

    Chief Financial Officer

     

     

     

    3

     

    Get the next $UPXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ET

      TAMPA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that it will host a fireside chat with Allan Marshall, Chief Executive Officer, and Brian Rudick, CFA, Chief Strategy Officer, on Thursday, June 26, 2025, at 11:00 a.m. ET. During the fireside chat, management will discuss the digital asset treasury company business model, Upexi's multiple compounding value accrual mechanisms, and the Company's strategy to grow its lead as the premier Solana treasury company. Fireside Chat

      6/12/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Joins Webull Corporate Connect Service Platform

      Enables Upexi to build a community and foster relationships with Webull's 24 million registered users Connect with the Company on Webull here TAMPA, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced joining the Webull Corporate Connect Service (CCS) platform to increase engagement and transparency with investors. Upexi's portal on the Webull Corporate Connect Service provides a direct communication channel for shareholders and potential investors, reinforcing the Company's commitment to engaging with the

      6/9/25 9:00:56 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Approved for Options Trading on Nasdaq

      TAMPA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that options on its common stock are approved for trading on the Nasdaq Options Market. The options will trade under the ticker symbol "UPXI" and include a range of standard expiration dates and strike prices. The listing of options on UPXI shares provides investors with additional tools for managing risk and capitalizing on the Company's performance and future growth prospects. "The introduction of options trading is a milestone that reflects Upexi'

      6/5/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Upexi Inc.

      S-1/A - UPEXI, INC. (0001775194) (Filer)

      6/11/25 5:00:35 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      6/9/25 5:00:19 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFR14A filed by Upexi Inc.

      DEFR14A - UPEXI, INC. (0001775194) (Filer)

      6/2/25 5:11:23 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

      3 - UPEXI, INC. (0001775194) (Issuer)

      6/3/25 6:04:17 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care